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DOI 10.1016/j.ccr.2010.04.026SUMMARYIn mice, Lkb1 deletion and activation of KrasG12D results in lung tumors with a high penetrance of lymph node
and distant metastases. We analyzed these primary and metastatic de novo lung cancers with integrated
genomic and proteomic profiles, and have identified gene and phosphoprotein signatures associated with
Lkb1 loss and progression to invasive and metastatic lung tumors. These studies revealed that SRC is acti-
vated in Lkb1-deficient primary and metastatic lung tumors, and that the combined inhibition of SRC, PI3K,
and MEK1/2 resulted in synergistic tumor regression. These studies demonstrate that integrated genomic
and proteomic analyses can be used to identify signaling pathways that may be targeted for treatment.INTRODUCTION
Lung cancer is the leading cause of cancer mortality worldwide.
Genetic analyses and gene expression profiling of primary
human lung tumors have identified several aberrant signaling
pathways involved in the initiation of non-small cell lung cancer
(NSCLC) (Bild et al., 2006). Although many of these pathwaysSignificance
Although large-scale genomic analyses of non-small cell lung c
cancer genetic alterations, studies defining the pathways der
LKB1 inactivation is found in up to 30% of human NSCLCs, an
of lymph node and distant metastases. Our analyses of prim
shown that progression to metastatic lung cancer is associate
work, we employ these signatures to design an effective, rationare also likely to be involved in NSCLC progression and
metastases, it is clear that the metastatic phenotype requires
additional pathway perturbations that regulate cell motility, cell
adhesion, the epithelial to mesenchymal transition (EMT),
and extracellular matrix remodeling (Nguyen and Massague,
2007). Because the development of metastases causes much
of the morbidity and incurability of epithelial cancers, there isancers (NSCLCs) have yielded a better understanding of lung
egulated in tumor progression and metastases are limited.
d Lkb1-deficient lung tumors in mice have a high penetrance
ary and metastatic Lkb1-deficient mouse lung tumors have
d with unique gene and phosphoprotein signatures. In this
al therapeutic strategy to treat Lkb1-deficient lung cancers.
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process.
The paucity of matched primary and metastatic human lung
tumors has made it difficult to examine the genetic changes
involved in the progression and metastasis of NSCLC. Studies
using genetically engineered mice have demonstrated that the
activation of certain combinations of oncogenes is sufficient
for lung tumor initiation (Engelman et al., 2008; Jackson et al.,
2001; Ji et al., 2006a, 2006b) and that additional genetic events
are required for tumor progression (Iwanaga et al., 2008; Jack-
son et al., 2005) or metastases (Ji et al., 2007; Kim et al.,
2009). We recently showed that the loss of the Lkb1 tumor
suppressor gene in Kras-driven lung tumors results in metas-
tases to lymph node and distant sites in mice (Ji et al., 2007).
Moreover, we and others have shown that LKB1 is inactivated
by point mutations or deletions in at least 15%–35% of NSCLC
and concurrent KRAS and LKB1 mutation is observed in
4%–10% of NSCLC (Carretero et al., 2004; Koivunen et al.,
2008; Ji et al., 2007; Matsumoto et al., 2007; Sanchez-Cespedes
et al., 2002).
In humans, germline mutation of LKB1 results in the Peutz-
Jeghers syndrome, a familial cancer syndrome characterized
by intestinal hamartomas and an increased risk for epithelial
cancers, including lung cancers (Hearle et al., 2006). The LKB1
gene encodes a serine/threonine kinase that phosphorylates
several substrates, many of which are also kinases (Alessi
et al., 2006). However, identification of the pathways responsible
for the prometastatic effects of Lkb1 loss has yet to be made.
To identify altered signal transduction pathways involved in
the progression and metastases of Lkb1-deficient lung tumors,
we have performed an unbiased, integrated analysis of genomic
and phosphoproteomic signatures of primary and metastatic
mouse lung tumors.
RESULTS
Lkb1-Deficient Metastatic Lung Tumors Harbor Unique
Gene Expression Changes
Lung-specific activation of mutantKrasG12D results in bronchoal-
veolar hyperplasia and low grade adenocarcinomas (Jackson
et al., 2001). We recently observed that concomitant loss of
the Lkb1 tumor suppressor gene leads to a broadened histologic
spectrum of lung tumors that have a high propensity for local
invasion and metastases (Ji et al., 2007). To identify the gene
expression changes associated with the invasive and metastatic
progression of Lkb1-deficient mouse lung tumors, we compared
RNA expression profiles from 9 Kras and 9 Kras/Lkb1 primaryFigure 1. A Gene Expression Signature of Metastasis Derived from
Survival in Human NSCLC
(A) Generation of an expression signature of metastasis. Kras/Lkb1 primary tumo
ential expression analysis and an FDR of < 0.01. A total of 757 unique transcripts w
signature (Mets).
(B) Kaplan-Meier analysis of the Director’s Challenge Consortium data set (N = 180
tumors comparing the overall survival between tumors showing activation (red lin
represents Mets signature activated. The green line represents Mets signature in
(C) Heat map of relative enrichment scores derived by gene set enrichment analys
rows (red, significant enrichment of overexpressed genes; green, significant enr
panel shows the aggregate enrichment scores for each of the three classes of t
Table S1 and Figure S1.tumors as well as 16 Kras/Lkb1 metastases (lymph node
and distant sites). Unsupervised hierarchical clustering of the
samples revealed three distinct clusters corresponding to
the following groups: (1) primary lung tumors with activated
Kras G12D, (2) primary lung tumors with activated Kras G12D and
Lkb1 loss, and (3) metastases from lung tumors with activated
Kras G12D and Lkb1 loss (see Figure S1A available online).
To better characterize the molecular alterations associated
with Lkb1 loss and metastasis, we derived expression signatures
from our mouse lung tumors that reflected the gene expression
changes induced by Lkb1 loss in primary tumors (Lkb1) by
comparing primary Kras tumors with primary Kras/Lkb1 tumors
and changes associated with metastases (Mets) by comparing
Kras/Lkb1 primary tumors to Kras/Lkb1 metastases. We used
a two-class unpaired differential expression analysis and a
false-discovery rate (FDR) of < 0.01. The resulting ‘‘Lkb1’’ and
‘‘Mets’’ gene signatures contain 727 and 757 differentially
expressed genes, respectively (Figure 1A). In aggregate, these
results indicate that Lkb1 loss induces significant transcriptional
changes in primary cancers and that there are further gene
expression alterations that characterize the progression to
lymph node and distant metastasis.
A Cross-Species Comparison across Mouse and Human
Data Sets Validates an Expression Signature
of Metastases as Prognostic in Human NSCLC
We next sought to determine whether this Mets signature pre-
dicted clinical outcome in human lung cancer patients. Using
the human orthologs of the murine genes in the Mets signature,
we interrogated two publicly available gene expression data sets
of primary NSCLCs, annotated for either overall survival and
histologic grade (Director’s Challenge Consortium data set,
Shedden et al., 2008) or metastasis-free recurrence (MSKCC
data set 2, Nguyen et al., 2009). The gene expression profiles
of these human NSCLCs were queried for the presence or
absence of our Mets expression signature as defined by coordi-
nate upregulation and downregulation of overexpressed or
underexpressed genes from the Mets signature.
Consistent with the notion that our Mets gene signature
correlates with a proclivity toward metastasis, patients with
tumors expressing the Mets signature had a significantly worse
survival and increased occurrence of metastasis than did
patients with tumors without Mets signature expression in
these two data sets (Figure 1B). In contrast, the Lkb1 signature,
generated by comparing Kras tumors to Kras/Lkb1 primary
tumors, had no prognostic value (data not shown). These
data suggest that the same gene expression changes induceda Kras-driven, Lkb1-Deficient Mouse Lung Cancer Model Predicts
rs were compared with Kras/Lkb1 metastases using two-class unpaired differ-
ere significantly differentially deregulated and used to define a metastatic gene
) and Memorial Sloan Kettering Cancer Center data set 2 (N = 98) of human lung
e) or inactivation (green line) of our mouse-derived Mets signature. The red line
activated.
is. Tumors are represented in columns and genes signatures are represented in
ichment of under-expressed genes; black, not significant; p < 0.05). The right
umors (Kras, Kras/Lkb1 primary tumors and Kras/Lkb1 metastases). See also
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this murine model faithfully recapitulate those associated with
the development of advanced incurable disease in human
primary NSCLC and might be useful to prognosticate patients
with early stage lung cancer. The disparity in the ability of the
Lkb1 signature and the Mets signature in predicting survival
suggest that either there is a subset of cells in the primary
tumor that is destined for metastases that cannot be discerned
from expression analyses of the whole tumor or that additional
expression changes developed at the site of metastases from
cancer-stromal cell interactions. Lastly, and as shown on
Figure S1B, the repressed component of the Mets signature
showed a strong and significant correlation with the human
samples that are mutant for both KRAS and LKB1 in the
University of North Carolina data set (Ji et al., 2007).
Lkb1-Deficient Metastases have Upregulation
of EMT-Associated Gene Signatures
Activation of oncogenic signaling pathways has been shown to
induce broad gene expression changes that can be used to
generate gene expression or metagene signatures (Nevins
and Potti, 2007). In order to better understand the biological
basis for tumor metastasis in this model, we compared genes
that were upregulated in the metastatic progression of these
mouse lung tumors to known lists of transcripts associated
with specific alteration in known pathways. Using gene set
enrichment analyses, we identified gene signatures that were
significantly enriched in our Kras/Lkb1 metastases relative to
our primary Kras and Kras/Lkb1 lung tumors (Segal et al.,
2004). Specifically, a collection of curated gene sets (Table
S1) provided by the Molecular Signatures Database (MsigDB,
broad.mit.edu/gsea/msigdb) and those collected from the liter-
ature (Ben-Porath et al., 2008; Bild et al., 2006; Cole et al.,
2008; Onder et al., 2008) were used to interrogate our gene
expression data set with the Genomica analysis tool (genomi-
ca.weizmann.ac.il).
A total of 32 of the 51 curated, cancer-related, gene sets
appeared to be significantly enriched and highly expressed
(p < 0.05, FDR < 0.05) in our data set of Kras/Lkb1 metastases
relative to Kras and Kras/Lkb1 primary lung tumors (Figure 1C).
This included a number of gene signatures implicated in the
metastatic process such as focal adhesion alterations, EMT,
increased TGF-b and b-catenin signaling, as well as embryonic
stem (ES) cell expression signature and transcription factors
implicated in ES cell phenotype such as TCF3 and OCT4 (Ben-
Porath et al., 2008; Bild et al., 2006; Cole et al., 2008; Onder
et al., 2008). A number of these findings were validated. For
example, the canonical EMT markers (Kalluri and Weinberg,Figure 2. Phosphoprotein Profiling of Human Cell Lines and Murine Tu
(A) Venn diagram of phosphotyrosine sites identified in Kras/Lkb1 primary versus
2B) expressing shRNA to LKB1 (LKB1D) or a nontargeting shRNA (NT). Western
BEAS-2B cells. Red numbers in brackets show differentially increased or decrea
(B) Table of coordinately regulated, LKB1-dependent phosphotyrosine sites. De
regulated across data sets are listed and include the phosphorylated protein, the
log2 ratios; blue, negative log2 ratios), as well as the putative upstream kinase. Th
of the genes encoding these proteins between Kras/Lkb1 (primary or mets) vers
green dots = significantly underexpressed, and orange dots = no significant ch
HPRD and Swissprot databases. Superscript 2 indicates upstream kinases obta2009), Vimentin, Snail, Twist1, N-cadherin, Acta2, and fibro-
nectin seen in this signature were validated by real-time poly-
merase chain reaction (RT-PCR) (Figure S1C). Multiplex bead
assay confirmed the elevated TGF-b levels in lysates from
Kras/Lkb1 metastases (Figure S1D). Furthermore, immunostain-
ing demonstrated the presence of canonical EMT markers such
as vimentin and fibronectin in both Kras/Lkb1 primary and meta-
static tumors (Figure S1E). Although components of these onco-
genic signatures were observed in Lkb1-deficient primary
tumors, their levels appeared to be higher in Lkb1-deficient
metastases (Figure 1C and Figures S1C–S1E). These results
suggest that additional molecular events cooperate with Lkb1
loss to maximally activate these pathways during metastatic
progression.
Phosphoscan of LKB1-Deficient Cells Identifies
Activation of SRC Family Kinases
To complement our transcriptional analysis, we assessed how
loss of Lkb1 impacted tyrosine kinase signaling cascades. We
hypothesized that if Lkb1 loss resulted in significant activation
of specific tyrosine kinases, then we should detect increased
phosphorylation of their respective substrates. To complement
the analysis of murine tumors, we generated paired LKB1 and
control knockdown cells in the BEAS-2B human bronchial
epithelial cell line (Reddel et al., 1988), which is immortalized
with SV40 Large T antigen, (BEAS-2B-LKB1D and BEAS-2B-
NT, respectively) and in the KRAS mutant, LKB1 wild-type
NSCLC cell line H358 (H358-LKB1D and H358NT), which has
been previously shown not to express markers of EMT (Thomson
et al., 2008) (Figure 2A). These paired human cell lines, along
with our mouse lung primary and metastatic tumors, were
used for generating phosphotyrosine signatures with previously
described methods (Rikova et al., 2007). Specifically, whole cell
extracts from cell lines or pooled tissue lysates (two pools with
three tumor samples each from Kras, Kras/Lkb1 primary tumors,
and Kras/Lkb1 metastases) were immunoprecipitated with a
phosphotyrosine specific antibody, and the immunoprecipitates
were subjected to mass spectrometry (MS) analysis to identify
and quantify phosphopeptides.
We identified 441, 259, and 363 phosphotyrosine sites in
BEAS-2B, H358 and mouse lung tumors, respectively, that
were enriched in the absence of LKB1 (Figure 2A). Forty-one of
these LKB1-affected tyrosine phosphorylated peptides were
noted to overlap across all three data sets (Figure 2A, cluster
A), whereas an additional 26 peptides and 10 peptides were
noted to overlap between the BEAS-2B / mouse tumor and
H358 / mouse tumor data sets, respectively (Figure 2A, clusters
B and C). An examination of the putative upstream kinasesmors
metastatic murine tumors and isogenic paired cell lines (NCI-H358 and BEAS-
blots show the effectiveness of LKB1 knockdown (LKB1D) in NCI-H358 and
sed phosphotyrosine sites in each comparison.
tails of the LKB1-dependent phosphotyrosine sites found to be coordinately
tyrosine site, heatmaps of log2 ratios of indicated comparisons (red, positive
e GEP (gene expression profiling) data column indicates the level of expression
us Kras murine tumors comparisons (red dots = significantly overexpressed,
ange). Subscript 1 indicates upstream kinases obtained from PhosphoELM,
ined from NetworKIN database (see also Figure S2).
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Figure 3. Focal Adhesion Is Impaired in Kras/Lkb1 Tumors and Metastases
Most relevant findings from our genomic and proteomic analysis were depicted on the focal adhesion KEGG pathway. Proteins labeled in red were hyperphos-
phorylated in the Phosphoscan analysis comparing Kras/Lkb1 primary tumors and metastases within the Phosphoscan analysis comparing Kras/Lkb1 primary
tumors and metastases with Kras alone tumors (Figure 2B). Proteins labeled in orange were found overexpressed (or their signatures were enriched) in the gene
expression profiling comparing Kras/Lkb1 primary tumors and metastases with Kras alone tumors (Figures 1A and 1C).
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a number of kinases were activated in association with LKB1
deficiency. These analyses pointed to a particularly central role
for SRC activation that was not only highly phosphorylated, but
that is also predicted to be an upstream kinase for 13 sites of
40 differentially phosphorylated proteins among our data sets
(Figure 2B). Moreover, Kras/Lkb1 primary tumors and metas-
tases showed a significant hyperphosphorylation of a Src
substrates signature, as assessed by Gene Set Enrichment Anal-
ysis (GSEA) (Figure S2A).
The Nonreceptor Tyrosine Kinases, SRC and Focal
Adhesion Kinase, Are Activated by LKB1 Loss
We speculated that integration of the gene expression and phos-
phoproteomics data sets would be a powerful approach to iden-
tify functionally significant molecular alterations in Lkb1-deficient
lung cancers. We noted that gene signatures of focal adhesion
activation were highly enriched in metastases from Kras/Lkb1
lung tumors (Figure 1C). Focal adhesions are dynamic subcel-
lular structures known to mediate cell attachment to the extracel-
lular matrix and are composed of over 50 proteins including
focal adhesion kinase (FAK or PTK2), Paxillin, and SRC (Burridge
et al., 1997; Playford and Schaller, 2004; Yeatman, 2004). As
noted above, SRC activation was the most prominent signature
emerging from our phosphoproteomic analysis and there was552 Cancer Cell 17, 547–559, June 15, 2010 ª2010 Elsevier Inc.also strong evidence for FAK activation. To better integrate our
data examining the impact of LKB1 loss on the focal adhesion
pathway, components of the pathway upregulated at the gene
expression or tyrosine phosphorylation level were colored yellow
and red, respectively, and visualized on a KEGG pathway map
(Figure 3). The results appear to show convergence on the acti-
vation of SRC, FAK, and their downstream pathways by Lkb1
loss and implicate alterations in the expression and activity of
focal adhesion regulators in the pathogenesis of Lkb1-deficient
lung cancers.
SRC and FAK activation results in focal adhesion disassembly
and turnover, through downregulation of RhoA, resulting in
increased cellular motility (Arthur et al., 2000; Yeatman, 2004).
Given the key role of cellular motility and migration in the process
of metastasis, we next determined whether LKB1 regulates
these key components of focal adhesion dynamics. To this
end, whole cell extracts of the H358 cells expressing control
shRNA (NT) or four different shRNA sequences targeting LKB1
(A, B, C, and D) were immunoblotted using antibodies against
the activating tyrosine phosphorylation sites in SRC, and FAK
(Y416 and Y576/577, respectively). As shown in Figure 4A, LKB1
knockdown led to activation of the focal adhesion complex,
specifically SRC and FAK. Moreover, consistent with LKB1’s
established role as a regulator of the AMPK/TSC/mTORC1 axis
(Carretero et al., 2007; Shaw et al., 2004), H358 LKB1-deficient
Figure 4. LKB1 Knockdown Activates EMT
Markers, Mediators of Focal Adhesion
Dynamics, and Enhances Cell Motility
(A) Western blot analysis of NCI-H358 cells (LKB1
wild-type, KRAS G12C mutant) infected with
lentiviruses encoding four different sequences of
shRNAs (LKB1A– LKB1D) targeting LKB1 or non-
targeting shRNA (NT). Whole cell lysates were
imunoblotted with antibodies specific to LKB1 or
tyrosine-specific antibodies against SRC (Total
and Y416), FAK (Total and Y576), paxillin (Total
and Y118), E-Cadherin, and vimentin. a/b-Actin
(Actin) serves as a loading control.
(B) Representative photographs of scratched
areas of confluent monolayers of NCIH358 cells
expressing a shRNA to LKB1 (LKB1D) or a nontar-
geting shRNA (NT) 12 hr after wounding with
a pipet tip.
(C) NCI-H358 cells expressing shRNA to LKB1
(LKB1D) or nontargeting shRNA (NT) were sub-
jected to invasion assay in Boyden chambers
coated with matrigel for 48 hr using 10% FBS as
chemoattractant. Data is graphed as mean of
three replicates and standard deviation (± SD).
(D) Mean tumor volume measurements of NCI-
H358 xenografts. The human lung cancer cells,
NCI-H358, expressing shRNA to LKB1 (LKB1D)
or a nontargeting shRNA (NT) were grown subcu-
taneously in athymic nude mice. After 14 days the
tumors were measured and the tumor volume
calculated (error bars represent 1 SD; n = 5,
p = 0.043).
(E) Immunohistochemical staining of human
vimentin and human cytokeratins in NCIH358 NT
and LKB1D xenografts. See also Figure S3.
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(S79) phosphorylation, as well as an increase of S6 (S240/S244)
phosphorylation (Figure S3A).
Because Phosphoscan and western blot analyses detect
a phosphorylation site (Y416) that is common to all SRC family
kinases (SFKs) including SRC, FYN, LYN, LCK, HCK FGR, and
YES, we interrogated the phosphorylation status of SFKs
affected by LKB1 loss in NCI-H358 and A549 cell lines using a
Luminex bead assay. As shown in Figures S3B and S3C, H358
cells preferentially activate SRC and LYN, whereas A549 acti-
vates only SRC. In both cases, LKB1 loss promoted activation
of SFKs. In addition, analyses of the protein lysates from
H358-LKB1D and H358-NT cells with a protein array with site-
specific phosphoantibodies further validated SRC, FAK, and
other targets obtained by MS analyses of Kras/Lkb1 murine
model (Figure S3D).Cancer Cell 17, 547–5These changes in SRC and FAK sug-
gest impaired adhesion and increased
cellular motility (Yeatman, 2004). To
assess whether loss of LKB1 affects the
motility of these NSCLC cells, we per-
formed a scratch assay. H358 cells with
LKB1 knockdown (LKB1D) migrated
more rapidly into the scratched space
than the control cells (NT), whereas prolif-eration and viability of the two cells lines were identical in vitro
(Figure 4B and Figure S3E). LKB1 loss also increased in vitro
invasion of H358 cells, as assessed by Boyden chamber assay
(Figure 4C). Therefore, loss of LKB1 appears to increase the
kinase activity of several key proteins involved in focal adhesion
dynamics and promote cell motility and invasion.
We also determined the consequences of LKB1 loss in NSCLC
cells in vivo. To this end, we grew H358-LKB1D and H358-NT
cells as subcutaneous xenograft tumors in nude mice and
measured mean tumor volume 2 weeks after implantation.
Tumors derived from H358 LKB1-deficient cells were signifi-
cantly larger than those expressing a nonspecific shRNA, sug-
gesting that loss of LKB1 promotes primary tumor growth in
addition to metastasis (Figure 4D). Immunohistochemical (IHC)
staining with antibodies that specifically recognize human (but
not mouse) antigens showed increased levels of vimentin in the59, June 15, 2010 ª2010 Elsevier Inc. 553
Figure 5. LKB1 Knockdown Cooperates
with FAK and SRC Inhibition to Prevent
Adhesion to Collagen and Migration in
NCI-H358 Cells
(A) Exponentially growing NCI-H358 cells express-
ing shRNA to LKB1 or a nonspecific shRNA (NT)
were seeded at 5 3 105 cells in wells coated with
collagen I, collagen IV, or bovine serum albumin
and allowed to adhere to the matrices in the pres-
ence of dimethyl sulfoxide (DMSO, control), 10 nM
Dasatinib (SRC inhibitor) or 100 nM PF 573228
(FAK inhibitor). After 90 min, loose cells were
washed off and adherent cells were fixed and
stained.
(B) NCI-H358 cells expressing shRNA to LKB1
(LKB1D) or a nonspecific shRNA (NT) were seeded
at 13 105 cells/well onto collagen I-coated 96-well
plates containing DMSO or increasing concentra-
tions of Dasatinib or PF573228, and incubated for
90 min. Data points represent the average of
normalized values expressed as percentage of
adhesion compared with DMSO-treated cells,
from two independent experiments performed in
triplicate; error bars represent SD.
(C) NCI-H358 cells expressing shRNA to LKB1
(LKB1D) or a nonspecific shRNA (NT) were seeded
at 1 3 105 cells/well onto 24 wells, and cells were
allowed to grow until forming confluent mono-
layers. The monolayer was scratched with a pipet
tip to form a wound and the cells were grown in
media containing DMSO or increasing concentra-
tions of Dasatinib or PF573228. Twelve hours
after wounding of the confluent monolayers, the
wound closure was measured and expressed as
percentage closure of the original wound. Data
are graphed as mean of three replicates ± SD.
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in agreement with the previous results suggesting that loss of
LKB1 promotes EMT (Figure 4A and Figure S1E). Elevated vi-
mentin staining was particularly prominent at the edge of tumors
suggesting that the EMT in the LKB1-deficient tumor cells may
have also involved signals from the adjacent stromal cells
(Figure 4E). In agreement to these observations, H358 cells
without LKB1 (LKB1D) released significantly more TGF-b1/2
than H358 control (NT) cells and nuclear b-catenin accumulation
was more prevalent in LKB1D than in NT cells (Figures S3F and
S3G). These observations support the notion that LKB1 loss
plays an important role in EMT.554 Cancer Cell 17, 547–559, June 15, 2010 ª2010 Elsevier Inc.LKB1 Loss Heightens Dependence
on SRC and FAK Signaling for Cell
Adhesion and Migration
Our integrated gene expression and
Phosphoscan results suggest that LKB1
loss might promote metastasis through
activation of SRC and FAK signaling.
Metastasis is a multistep process in-
volving cell interactions with extracellular
matrix (ECM) components, increased cell
migration and tumor invasion (Mitra and
Schlaepfer, 2006). These individual pro-
cesses can both modulate and bemodulated by SRC and FAK activity (Huveneers and Danen,
2009; Shibue and Weinberg, 2009). We hypothesized that
SRC/FAK activation induced by LKB1 loss resulted in an
increased dependence upon these signaling pathways for cell
adhesion to ECM. To test this hypothesis, we plated 53 105 cells
with or without LKB1 knockdown on tissue culture wells coated
with collagen I, collagen IV, fibronectin, laminin I, fibrinogen, or
BSA in the presence of the SRC-family kinase inhibitor Dasatinib
or the FAK inhibitor PF573228 (Johnson et al., 2005; Slack-Davis
et al., 2007). Among the ECM components tested, only collagen I
or IV could promote the adherence of H358 cells (Figure 5A and
data not shown). Knockdown of LKB1 in H358 cells did not have
Figure 6. Combination Therapy with PI3K,
MEK, and SRC Inhibitors Results in Syner-
gistic In Vivo Response of Lkb1-Deficient
Murine Lung Tumors
(A) Representative MRI images before and after
treatment for each group. Mice in each group
were MRI imaged then treated daily for 2 weeks
with 45 mg/kg BEZ235, 25 mg/kg AZD6244, and
15 mg/kg Dasatinib, and imaged again. Tumor
volumes were normalized to pretreatment tumor
volumes. The average tumor volumes of three to
seven mice in each treatment group are shown.
Error bars represent 1 SD (p < 0.05 BEZ/AZD/
Dasatinib treated versus pretreatment).
(B) H&E staining. H&E sections of representative
Kras/Lkb1 tumors from animals treated with the
indicated drugs. See also Tables S2 and S3.
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to either collagen I or IV. However, treatment of H358 cells with
Dasatinib or PF573228 resulted in a dose-dependent decrease
in cell adhesion that was more prominent in H358 cells with
LKB1 knockdown (Figure 5B). Similar results were obtained
when H358 cells with or without LKB1 expression were
examined for the effects of Dasatinib and PF573228 on cell
migration (Figure 5C). These observations support the notion
that the activation of SRC and FAK due to LKB1 loss promotes
dependence upon these signaling pathways for cell migration
and adhesion to extracellular matrix components as well as
migration.
Combined Inhibition of PI3K-mTOR, MEK, and SRC
Family Kinases Results in Synergistic In Vivo Tumor
Response in LKB1-Defective Lung Tumors
We had previously observed that dual inhibition of PI3K-mTOR
and MEK with BEZ235 (a PI3K-mTOR inhibitor) and AZD2644
(a MEK1/2 inhibitor) resulted in an 80% reduction of tumor
volume of Kras-dependent murine lung tumor model (EngelmanCancer Cell 17, 547–5et al., 2008). Surprisingly, treatment of
Kras/Lkb1 mice with the same combina-
tion showed that these lung tumors
were largely unresponsive (Figure 6A).
Because our integrated gene expression
and phosphotyrosine profiling as well as
in vitro cell culture studies demonstrated
that SRC is activated by LKB1 loss
(Figures 1C and 2B, and Figures S2 and
S3A–S3C), we hypothesized that inhibi-
tion of SRC by Dasatinib might restore
sensitivity of Kras/Lkb1 lung tumors to
PI3K and MEK inhibition. To examine
the therapeutic impact of SRC inhibition
in Kras/Lkb1 lung cancers, we treated
established Kras/Lkb1 lung cancers with
Dasatinib alone, the combination of
BEZ235 and AZD2644 (AZD/BEZ), or the
combination of all three agents (Dasati-
nib/AZD/BEZ). Although Kras/Lkb1 lungtumors did not respond to Dasatinib or BEZ/AZD, the triple
combination Dasatinib/BEZ/AZD resulted in significant tumor
regression as detected by serial magnetic resonance imaging
(MRI) (Figure 6A) and histology (Figure 6B). These in vivo data
suggest that Lkb1 loss results in reduced sensitivity to the
combined inhibition of PI3K and MEK, at least in part, through
activation of SRC. Moreover, although Dasatinib alone in Kras/
Lkb1 lung cancer model did not provide overall survival benefit
over vehicle in this Kras/Lkb1 lung cancer model, it blocked
metastasis (Table S2).
Gene expression profiling of short term treated tumors
showed that all treatments were able to revert Lkb1 and Mets
signatures (Table S2). Interestingly, Dasatinib alone induced
downregulation of SRC, TGF-b, and MEK signatures, but not
AKT, EMT, and ES signatures. Triple combination downregu-
lated SRC, TGF-b, MEK, as well as AKT, EMT, and ES signa-
tures. This analysis supports the observation that Dasatinib
synergizes with BEZ/AZD in inhibiting signal transduction
pathways that are important in the proliferation and survival of
Kras/Lkb1-driven cancer cells.59, June 15, 2010 ª2010 Elsevier Inc. 555
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Cancer genomic studies have established a number of onco-
gene and tumor suppressor pathways as important for the
initiation and maintenance of neoplastic lesions in NSCLC.
However, the molecular alterations necessary for invasion and
metastasis of NSCLC are less well-defined. We have previously
reported that deletion of the Lkb1 tumor suppressor gene in
the context of Kras-driven murine lung tumors promotes inva-
sion and metastasis (Ji et al., 2007). Here we extend these
findings to show that Kras/Lkb1 primary and metastatic tumors
have upregulated expression of markers and inducers of
EMT. Furthermore, through an integrated genomic and phos-
phoproteomic analysis of mouse lung primary and metastatic
tumors, we have determined that two key modulators of focal
adhesion dynamics, SRC and FAK, are upregulated by Lkb1
loss during NSCLC progression. Similarly, LKB1 loss in vitro
also resulted in SRC activation, increased motility, and SRC-
dependent adhesion. In fact, migration was selectively abro-
gated by SRC and FAK inhibition in LKB1-deficient cells.
Finally, whereas Kras mutant lung tumors are sensitive to the
combined inhibition of the PI3K and MEK pathways, we have
found that Kras/Lkb1 tumors are resistant to these inhibitors,
and that sensitivity can be restored by additional targeting of
SRC. It also important to note that addition of Dasatinib to
combined PI3K/MEK inhibition induced tumor shrinkage in
the LKB1-deficient tumors. This reveals an important role for
SFKs in tumor growth and promoting resistance to combined
PI3K/MEK inhibition. Indeed, in addition to their prominent
roles in tumor migration and adhesion, SFKs are also essential
for transducing signals from RTKs and integrins to promote cell
survival and proliferation (Yeatman, 2004). It was somewhat
surprising that single-agent Dasatinib led to increased volume
of Kras/Lkb1 tumors (Figure 6) and persisting Akt and EMT
signatures (Table S3). Although we cannot fully explain this
observation, it is tempting to speculate that SRC inhibition
led to loss of a feedback mechanism resulting in increased
tumor growth or to a change in the interactions between tumor
cells and stroma or immune cells resulting in tumor growth.
Collectively, these results point toward a mechanism under-
lying the increased propensity for metastases seen in Lkb1-
deficient lung tumors and identify SRC as a molecularly target-
able pathway for the treatment of LKB1-deficient NSCLC in
humans.
Tumor metastasis is a complex, multistage process that
involves both initiating functions, such as invasion and angiogen-
esis, as well as metastasis progression functions such as extrav-
asation and survival (Nguyen and Massague, 2007). EMT has
been implicated in metastasis initiation and involves loss of
cell-cell junction proteins as well as a conversion of stationary
cells to motile cells capable of invading through the ECM
(Yang and Weinberg, 2008). Our gene expression analysis
suggests that LKB1 loss results in the aberrant expression of a
number of oncogenic pathways and transcription factors known
to be inducers of EMT such as SNAI1, TWIST1, and the TGF-b
and b-catenin pathways (Kalluri and Weinberg, 2009; Nguyen
and Massague, 2007; Yang and Weinberg, 2008). Although the
mechanism by which LKB1 loss promotes EMT remains to be
determined, we observe that NSCLC cells lacking LKB1 exhibit556 Cancer Cell 17, 547–559, June 15, 2010 ª2010 Elsevier Inc.higher nuclear localization of b-catenin and increased release
of TGF-b (Figures S3F and S3G) suggesting that LKB1 loss
may have a direct cell autonomous role in promoting the EMT
program. The expression signatures derived from Kras/Lkb1
metastasis enriched for EMT correlate with NSCLC patients
with metastatic potential and worsened survival (Figure 1B),
whereas expression signatures derived from Kras primary
tumors or Kras/Lkb1 tumors did not correlate with survival thus
have no prognostic value. Importantly, the presence of Mets
signature in primary tumor samples, including a subset of double
KRAS and LKB1 mutants, suggests that a subset of primary
tumors harbor cells destined for metastasis.
Part of the roadblock in defining the pathways involved in inva-
sion and metastases in human NSCLC has been the difficulty in
obtaining tissue from metastatic sites. Through the use of aKras-
driven, Lkb1-deficient genetically engineered mouse model of
lung cancer, we have been able to collect matched primary
and metastatic tumors and apply integrated gene expression
and phosphoproteomic analysis to define altered signal trans-
duction pathways. The utilization of complex murine cancer
models to identify signal transduction pathways altered in
cancer progression and metastases might serve as a paradigm
for other solid tumors that suffer from similar barriers to tissue
acquisition.
Previous work from our lab has shown that dual inhibition of
the PI3K and MEK pathways in Kras-driven murine NSCLC
results in synergistic tumor responses (Engelman et al., 2008).
Strikingly, Lkb1 loss renders these tumors substantially more
resistant to this therapeutic regimen; therefore, Lkb1 loss could
serve as a negative predictor of the responses to the therapy.
Despite the broad gene expression changes seen in the setting
of Lkb1 loss and progression to metastases, it is notable that
we were able to define a candidate mediator of Lkb1-deficient
tumor growth, SRC, in which additional inhibition—with Dasati-
nib—was able to restore sensitivity to inhibition of PI3K and
MEK in vivo. A limitation of this analysis is that Dasatinib is
a potent inhibitor of other kinases, e.g., ABL, which was also acti-
vated to a lesser degree in Lkb1-deficient tumors. Future studies
will determine the relative importance of SFKs versus other
Dasatinib targets in mediating the response to this agent. Lastly,
Kras/Lkb1 mice treated with Dasatinib alone did not show any
evidence of metastasis (Table S2). This further reinforces our
data that the Src family members are important mediators of
metastatic progression in Kras/Lkb1-driven lung cancer. In
conclusion, our results imply that despite the complex transcrip-
tional and signaling changes that occur in the setting of LKB1
loss and progression of NSCLC, these tumors may still be
addicted to isolated oncogenic events that can be successfully
therapeutically targeted.EXPERIMENTAL PROCEDURES
Mouse Colony and Tumor Collection
All mice were housed and treated in accordance with protocols approved by
the institutional care and use committees for animal research at the Dana-
Farber Cancer Institute. Kras and Kras/Lkb1 mice were treated with 5 3 106
p.f.u. adeno-Cre (University of Iowa viral vector core) intranasally as previously
described (Ji et al., 2007). Primary lung adenocarcinomas and metastases
were macrodissected and formalin fixed or frozen in liquid nitrogen and stored
at 80C until use.
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Formalin-fixed tissues were paraffin embedded, sectioned at 5 mm, and
hematoxylin and eosin (H&E) stained (Department of Pathology in Brigham
and Women’s Hospital). Unstained slides were deparaffinized in xylene
and rehydrated sequentially in ethanol. Antigen retrieval was performed by
boiling slides in 10 mM sodium citrate (pH 6.0) for 30 min. Primary antibodies
were diluted in TBST with 5% goat serum and incubated overnight at 4C
(see Supplemental experimental procedures for detailed list of primary
antibodies). Detection was performed using the avidin-biotin horseradish
peroxidase technique in which 3,300-diaminobenzidine was the chromogenic
substrate.
Analysis of Microarray Gene Expression Data
Gene expression profiling methods (Total RNA isolation and microarray pro-
cessing) are available in Supplemental Experimental Procedures. Clustering
and differential expression analyses were performed using the Gepas Analysis
suite (Tarraga et al., 2008) and GenePattern (Reich et al., 2006) with proce-
dures described in Supplemental Experimental Procedures. Genomica soft-
ware (http://genomica.weizmann.ac.il/) was used to identify enrichment
patterns of a custom collection of experimental signatures associated with
different phenotypes and cancer-related events (Ben-Porath et al., 2008;
Segal et al., 2004) (see Table S1 for detailed description). In brief, the data
were log2 transformed and mean centered. Genes whose expression was
2-fold or greater than the mean expression level were scored. Enrichment of
overexpressed or underexpressed genes that belong to each tested gene
signature was calculated using a hypergeometric test and an FDR calculation
to account for multiple hypothesis testing. (p < 0.05, FDR < 0.05). Finally, the
fraction of tumors showing significant enrichment for a particular gene signa-
ture in each class (Kras tumors,Kras/Lkb1 primary tumors and metastasis) was
calculated and assigned a p value according to the hypergeometric distribu-
tion (p < 0.01, FDR < 0.05).
Gene Set Enrichment analysis of short-term treated Kras/Lkb1 tumors was
performed using GSEA (http://broad.mit.edu/gsea) across the complete list of
genes ranked by signal-to-noise ratio.
UNC human lung cancer microarrays (Agilent custom 44,000 probe) anno-
tated withKRAS and LKB1 genetic status were mapped to mouse genes using
NCBI Homologene, retaining only one-to-one orthologs. Microarray data were
sample and gene standardized, and Lkb1 and Mets signature scores were
calculated as the median of the genes across the gene set. Statistical signifi-
cance was calculated using the Wilcoxon rank sum test.
Survival Analysis
The Director’s Challenge Consortium human primary lung adenocarcinoma
data set was downloaded from http://caarraydb.nci.nih.gov (experiment ID
1015945236141280:1) (Shedden et al., 2008). MSKK data set 2 was down-
loaded from http://cbio.mskcc.org/Public/lung_array_data (Nguyen et al.,
2009). Data sets were first log2 transformed, mean-centered data set and
loaded into Genomica software. Enrichment of genes that belong to our
murine-derived Mets signature was calculated as described above and each
patient was assigned an enrichment score. Positive and negative enrichment
scores for each individual were matched with survival data (time to last contact
or death) or recurrence of metastasis (metastasis-free survival). Kaplan-Meier
plots were created with Graphpad software. Statistical significance was calcu-
lated using the log-rank test.
Phosphopeptide Immunoprecipitation, Liquid-Chromatography
Tandem MS, and Phosphopeptide Analysis
We performed phosphotyrosine peptide identification and quantification as
described previously (Rikova et al., 2007). See Supplemental Experimental
Procedures for sample preparation and handling. For differential phosphoryla-
tion analysis, duplicated intensities were averaged, and fold-changes between
different experimental conditions were calculated. For KEGG classification
of the phosphoproteins, we used FatiGO software (www.babelomics.org)
(Al-Shahrour et al., 2004). A modification of GSEA (Subramanian et al., 2005)
with phosphoprotein sets instead gene sets (Figure S2A) was used to interro-
gate the PhosphoPoint database of tyrosine kinase substrates (http://kinase.
bioinformatics.tw) (Yang et al., 2008).Quantitative RT-PCR
A total of 50 ng RNA total RNA was reverse transcribed with the Superscript
cDNA Synthesis Kit (Invitrogen). RT-PCR reactions were prepared in triplicate
for each sample using primers and TaqMan probes purchased from Applied
Biosystems (see also Supplemental Experimental Procedures). Reactions
were run on an ABI PRISM 7900HT Sequence Detection System (Applied Bio-
systems). GAPDH was used as a reference for all reactions. Relative levels of
a gene were determined by DDCt method.Multiplex Bead Analysis
Quantification of TGF-b isoforms and Src family kinase activities were assayed
using Human TGF-b 1,2,3 Assay and SRC Family Kinase 8-Plex (Millipore),
respectively. Assays were performed according to the manufacturer’s specifi-
cations and analyzed with a Luminex 100 platform. Fluorescence intensity
from duplicate samples was averaged and transformed into protein concen-
tration using a calibration curve obtained with TGFb1, 2, and 3 standards.
For Src assay, activity was expressed in mean fluorescence intensity with
background correction from duplicate samples. Statistical significance was
calculated using a two-sided Student’s exact t test.Western Blot and Kinase Array Analysis
Parameters for western blot and antibodies are available in Supplemental
Experimental Procedures. Human phosphokinase arrays (R&D Systems)
were performed according to the manufacturer’s instructions. The percent
control activation/deactivation was determined by densitometric analysis
using ImageJ Software (NIH).Short Hairpin RNA Constructs, Lentiviral Infection,
and Small Interfering RNA Infection
Short hairpin RNA (shRNA) constructs cloned in pLKO.1 puro vector were
designed by the RNAi consortium and distributed by Open Biosystems.
shRNA sequences are provided with supplemental experimental procedures.
Stable polyclonal cell lines are established as described previously (Shima-
mura et al., 2008).Cell Migration, Invasion, and Adhesion Assays
Cell migration in cultures was measured using a two-dimensional in vitro
scratch motility assay. A 1 mm wide scratch was made on confluent monolayer
in tissue culture slides and allowed to grow under standard conditions for
12 hr. Repopulation of the cleared field was recorded using a Nikon inverted
TE2000 and migrated distance was quantified using Image J software. Inva-
sion and adhesion assays kits were obtained from Cell Biolabs and assays
were performed according to the manufacturer’s specifications. Details are
available in the Supplemental Experimental Procedures.Immunofluorescence Analysis
Cells were fixed on four-well chamber glass slides in methanol/acetone (1:1) at
–20C for 10 min and air dried. Primary block was done with 10% goat serum
(Sigma) and 0.05% Tween 20 in phosphate-buffered saline for 1 hr at room
temperature. A mouse monoclonal antibody for activated b-catenin (Millipore)
was diluted 1:50 in blocking buffer and incubated overnight at 4C. Rabbit anti-
mouse secondary antibody conjugated with Alexa488 dye (Invitrogen) was
diluted 1:100 in blocking buffer and incubated for 1 hr at room temperature.
Images were acquired using a Nikon inverted TE2000 microscope equipped
a Hamamatsu Orca ER digital CCD camera.In Vivo Xenograft Experiments
The 5- to 6-week-old female nu/nu mice (Charles River) were maintained under
pathogen-free conditions. Tumors were generated by injecting subcutaneous
5 3 106 cells mixed with reconstituted basement membrane Matrigel (BD
Biosciences) with 1:1 ratio in PBS. Animals were sacrificed 14 days after inoc-
ulation, and tumors were excised and fixed in formalin. Tumor measurements
were obtained using electronic calipers. Tumor volume was calculated using:
Tumor volume = (length 3 width2)/2. We compared tumor volumes of mice
using a two-sided Student’s exact t test.Cancer Cell 17, 547–559, June 15, 2010 ª2010 Elsevier Inc. 557
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Dual PI3K-mTOR inhibitor, NVP-BEZ235-AN (Novartis Institutes for Biomed-
ical Research) was reconstituted in one volume of N-methyl-2-pyrrolidone
(69118, Fluka) and nine volumes of PEG300 (81160, Fluka) and administered
by oral gavage. MEK inhibitor ARRY-142886 (AZD6244, Otava Chemicals)
and Dasatinib (LC Labs) were reconstituted in 0.5% methyl cellulose (Fluka)
and 0.4% polysorbate (Tween 80; Fluka) and administered by oral gavage.
Dosages are indicated in the figure legends.
MRI and Tumor Volume Measurement
We performed MRI measurements as described previously (Engelman et al.,
2008). Brief descriptions are available in the Supplemental Experimental
Procedures.
ACCESSION NUMBERS
Microarray data have been deposited at GEO with the accession number
GSE21581.
SUPPLEMENTAL INFORMATION
Supplemental Information includes three figures, three tables, and Supple-
mental Experimental Procedures and can be found with this article online at
doi:10.1016/j.ccr.2010.04.026.
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